This is demonstrated by reduced expression of proangiogenic genes in Irg1-deficient macrophages stimulated with tumor CM, as well as decreased angiogenesis in syngeneic pancreatic tumors after receiving Irg1-deficient macrophage therapy. This evidence concerns the gene ACOD1 and pancreatic neoplasm.